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Metachronous Eyelid Basal Cell Carcinoma on Opposite Eye and Lid: A Case 
Report 
Abstract 
Background: Basal cell carcinoma (BCC) is the most common eyelid malignancy, accounting for 
approximately 90% of malignant eyelid lesions.1 Despite its high occurrence rates, it is frequently 
misdiagnosed as one of the benign “lumps and bumps” that can be present on the eyelid. In the present 
case, a patient with a past BCC on the right upper eyelid presented with a left lower eyelid lesion which 
persisted for months before the patient sought evaluation by an eyecare provider. This benign-looking 
lash-line lesion was the only external sign of the malignancy found on the deep surface of the eyelid and 
later diagnosed as BCC. 
Case Report: A 74-year-old patient presented with a persistent eyelid lesion that was resistant to 
treatment for greater than 6 months. The small lesion was slightly suspicious in appearance. Further 
evaluation revealed a larger, more irregular lesion on the conjunctival surface of the eyelid. The patient 
was referred to an oculoplastic specialist for biopsy. Pathology confirmed the diagnosis of basal cell 
carcinoma. 
Conclusion: Once the lesion was properly diagnosed, the patient underwent Mohs micrographic surgery 
and eyelid reconstruction. This case will highlight the importance of prompt and thorough evaluation of 
suspicious eyelid lesions which are persistent and resistant to treatment in patients with a history of 
eyelid malignancy. 
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  Basal cell carcinoma (BCC) is the most common eyelid malignancy, accounting 
for approximately 90% of malignant eyelid lesions.1 Despite its high occurrence 
rates, it is frequently misdiagnosed as one of the benign “lumps and bumps” that 
can be present on the eyelid. In the present case, a patient with a past BCC on the 
right upper eyelid presented with a left lower eyelid lesion which persisted for 
months before the patient sought evaluation by an eyecare provider. This benign-
looking lash-line lesion was the only external sign of the malignancy found on the 




  A 74-year-old male presented for his annual diabetic eye exam. His medical 
history included insulin-dependent diabetes for five years without evidence of 
diabetic retinopathy; physiologic optic nerve cupping; and a right upper eyelid BCC 
treated successfully with Mohs micrographic surgery (MMS) approximately five 
years prior. He had not followed up with the oculoplastic surgeon after the 
procedure. 
 
  During his examination, the patient complained of a bump on his left lower eyelid 
for approximately 6-8 months. His primary care physician had originally prescribed 
antibiotic eye ointment, but the antibiotic ointment “did nothing” for the “bump.”  
During the same period, the patient also had been applying warm compresses to the 
lesion, but he stopped after a few weeks due to lack of improvement. At the time 
of his appointment, his only symptom related to the lesion was a foreign body 
sensation on blink.  
 
  On physical examination, best corrected acuity was 20/25 for the right eye and left 
eyes. All external testing including pupils, motilities, and confrontation visual 
fields were normal. Intraocular pressure was normal and symmetric. Scarring of the 
central right upper eyelid margin was consistent with the patient’s history of MMS 
and reconstruction was present. The left lower eyelid demonstrated a raised, firm, 
pearly lesion without telangiectasia and with mild interruption of the lash-line 
integrity. The patient did not report any tenderness when the lesion was palpated. 
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Figure 1 Left lower eyelid lesion 
 
Upon pulling down the lid and viewing the tarsal conjunctiva, a multilobulated 
cystic lesion was identified. (See Figure 2).  
 
 
Figure 2. Left lower eyelid tarsal conjunctiva, a multilobulated cystic lesion  
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There were no notable cornea findings. The patient’s dilated retinal exam was 
within normal limits; the previously noted optic nerve cupping was stable. No 
diabetic retinopathy was present in either eye.  
 
  This patient was referred to an oculoplastic specialist for biopsy of the left lower 
eyelid lesion. Biopsy confirmed the diagnosis of BCC and the patient was 




  Approximately 20% of periorbital skin lesions are malignant. Clinical 
differentiation between malignant and benign eyelid lesions may be challenging 
even for experienced providers. The most common benign lid lesions are chalazia, 
seborrheic keratoses and inclusion cysts. The most common malignancies are BCC, 
squamous cell carcinoma, and sebaceous cell carcinoma.2,3 Five main factors that 
should be evaluated for which increase malignancy risk are asymmetry, irregular 
borders, colors that are not uniform, diameter (greater than 6 mm), and enlargement 
or elevation (represented by a mnemonic ABCDE). Leung et al. proposed an 
additional three factors: lash-loss, ulceration, and infiltration (or mnemonic LUI) 
for identification of malignant lesions. In a study of 199 eyelid lesions these factors 
were the three most predictive of malignancy.3   
 
  Clinical differentiation among malignant lesions can be difficult as well. 
Sebaceous cell carcinoma is differentiated by its association with the glands of Zeis; 
it also has a characteristic yellow coloration due to lipoid deposition and can present 
with chronic localized blepharoconjunctivitis and chalazia. Squamous cell 
carcinoma may arise from pre-malignant lesions such as actinic keratosis, Bowen’s 
disease, or keratoacanthoma. It can present with varying features from 
erythematous scaly patches to ulcerated or nodular lesions.4 BCC is not easily 
differentiated from squamous cell carcinoma and diagnosis is often not determined 
until a biopsy is performed.2  
 
  Basal cell carcinoma of the eyelid most commonly presents as a pink or fleshy 
pearlescent nodule—occasionally with ulceration or telangiectasia.5 This nodular 
presentation accounts for up to 80% of cases on the head and face.6 A less common 
variant, morpheaform BCC, involves fibroblastic proliferation in addition to the 
classic tumor cell production. This type is more aggressive, has a higher recurrence 
rate, and requires greater caution when clearing excisional margins. The distinction 
is made histochemically by the presence of alpha-actin in the tumor stroma. 
Clinically, these lesions appear as white-yellow shiny plaques.7,6 Infiltrative BCC 
lesions are a variant in which the tumor cells extend deeper into the dermis than 
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typical nodular presentation; the extent of this type is often underestimated before 
a Mohs excision is performed. Superficial BCC is another rare variant which mostly 
occurs on body skin. It appears as an erythematous plaque like that associated with 
psoriasis or eczema.6   
 
  Eyelid BCC accounts for approximately 10% of all BCC lesions and primarily 
results from UV exposure. Additional risk factors include advanced age, 
immunosuppression, and exogenous carcinogens.6,8 The incidence of BCC on 
eyelids is similar in females and males and higher in Caucasian populations.6,9 
According to Hamada et al., 76% of lesions are located on the lower eyelid,   
15% on the upper eyelid, and the remainder on the medial canthus and lateral 
canthus.10 
 
  The gold standard for diagnosis of BCC is biopsy and histopathology. Though 
rapid metastasis is not typical of BCC, location on the eyelid or adnexa still requires 
prompt and careful management by an oculoplastic specialist to avoid localized 
spread and to achieve an aesthetically pleasing and anatomically successful 
outcome.9 Treatment options include surgical intervention, radiation therapy, and 
drug therapies including Vismodegib or Imiquimod. Surgical resection is the most 
effective treatment option followed closely by wide local excision (with 
intraoperative frozen sections).1,11 The indication for radiation therapy or drug 
therapy is the inability to tolerate surgical resection, such as in a very sick patient 
or a patient with many serious comorbidities.11 Surgical resection is the most 
effective treatment option, with a cure rate greater than 95% (up to 99%) depending 
on size, variety and location. Other treatment options (e.g., radiation therapy) are 
generally less effective but still have a cure rate of over 90%.1  
 
  The recurrence rate of BCC after MMS is minimal at approximately 3%. 25% of 
recurrences occur within the first year and 75% within three years; the median time 
to recurrence being 19 months.12  Having a history of BCC or squamous cell 
carcinoma does increase the risk of developing additional lesions and a history of 
the latter increases the risk greater than the former. Patients who have a history of 
both BCC and squamous cell have a greater risk of subsequent BCC lesions than 
those with a history of BCC alone. Older age increases risk of future lesions; the 
average age of those with additional lesions being 69 years-old versus an average 
age of 63 years-old without.13  
 
  When Smedinga et al. investigated the risk of metachronous BCC lesions (isolated 
additional lesions identified later), they found that the greatest prognostic indicator 
was the number of previous BCC lesions. Other risk factors were skin sensitivity 
to sunburn (i.e., Fitzpatrick classification), pigmentation of previous lesions, and 
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lesion location. Utilizing the relative risks of these factors, a prognostic model was 
developed. A score was assigned for each risk factor and the sum used to determine 
a patient’s relative risk of developing metachronous lesions at 1 year, 3 years and 




  The present case should remind eye care practitioners of ABCDE and LUI factors 
for the evaluation of suspicious periorbital skin lesions. Also, that biopsy should be 
considered for any eyelid lesion that does not respond to treatment, particularly in 
patients with a history of eyelid malignancy.2  It is imperative to educate at-risk 
patients that regular monitoring and prompt evaluation are necessary for any new 
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